For a menopause-related search, choose a source category below. These categories also contain products for other uses; they are not a list of suitable treatments.
HORMONES AND SUBSTITUTES
Browse ingredients, then choose a strength and product. Ontario inventory only; not a treatment recommendation.
TESTOSTERONE ENANTHATE: products 1 to 2 of 2.
Prices below are the ministry's recorded amounts per source unit, not pharmacy quotes or the patient's payment. Different strengths, forms and package units are not directly comparable. The cost plan asks for quantity and refill details.
| Product / strength / form | Ontario listing | Recorded ministry price | Next step |
|---|---|---|---|
| Delatestryl 1000mg/5mL Oily Inj Sol-5mL PkDIN 00029246 | Listed, not a benefit | No price in this record | Requirements & sourcesBuild cost plan |
| Testosterone Enanthate Injection, USP 1000mg/5mL Oily Inj Sol-5mL PkDIN 02536315 | Limited Use, codes 397 | $35.5943per source unit | Requirements & sourcesBuild cost plan |
Not seeing a product? Search Canadian records by medication name or DIN. Absence from this Ontario extract does not establish non-coverage. Open an exact product for its dated Health Canada status; a listing is not a stock check.
Class sources and program rules
Ontario Ministry of Health: odb-formulary-ed43-extract-2026-08-26.xml, extract 2026-08-26. Ontario class index: formulary-ed43-front-matter.txt, Part V.
68:00 HORMONES AND SUBSTITUTES.
68:04 Corticosteroids.
68:08 Androgens.
68:12 Contraceptives.
68:16 Estrogens.
68:20:02 Oral Anti-Diabetic Agents.
68:20:06 Incretin Mimetics.
68:20:10 Insulins (Rapid Acting).
68:20:12 Insulins (Intermediate Acting).
68:20:14 Insulins (Long Acting).
68:20:16 Insulins (Pre-Mixed).
68:24 Parathyroid Agents.
68:28 Pituitary Agents.
68:32 Progestogens and Oral Contraceptives.
68:36 Thyroids.
68:38 Anti-Thyroids.
National Defence, WDH Guide to Menopause, 2026-09-17
Hormone Therapy (HT) previously called Hormone Replacement Therapy replaces estrogen and when needed, progesterone
Ontario Drug Benefit Formulary, Part V, 2026-09-03, p. 38
68:16 Estrogens
68:32 Progestogens and Oral Contraceptives